EPPENDORF GLOBAL SHOWCASE PRESENTATION The Ncardia approach and technology, leading in leveraging iPSC innovation at scale
Thursday, June 1, 2023 01:00 PM - 01:15 PM
Global Showcase Theater
Global Showcase Presentation
The Ncardia approach and technology, leading in leveraging iPSC innovation at scale
Presenter
Arie Reijerkerk, PhD, Director of Manufacturing Technology, Ncardia Services, The Netherlands
Human induced pluripotent stem cells (iPSCs) provide an unlimited source of stem cells that can be differentiated into any functional cell type closely mimicking human pathophysiology. This technology holds great potential to transform gene and cell therapy, drug discovery and regenerative medicine. However, the technical knowledge and capabilities required to leverage the full potential of iPSCs can limit its application.
For more than a decade, Ncardia has been pioneering innovations in iPSCs to transform therapeutic development in human healthcare. The combined iPSC expertise and in-house technology enables Ncardia offering unique integrated solutions for cell manufacturing and screening.
Starting with experimental scale, the manufacturing procedures are designed to scale up to state-of-the-art stirred-tank bioreactors in the shortest possible time frame, mitigating risks and with minimal batch-to-batch variability.
Join this presentation and gain insights about how Ncardia partners with biotech and pharma companies and constantly develops new manufacturing procedures for complex iPSC-derived cells which are characterized with identity and functional assays.
Presenter
Arie Reijerkerk, PhD, Director of Manufacturing Technology, Ncardia Services, The Netherlands
Human induced pluripotent stem cells (iPSCs) provide an unlimited source of stem cells that can be differentiated into any functional cell type closely mimicking human pathophysiology. This technology holds great potential to transform gene and cell therapy, drug discovery and regenerative medicine. However, the technical knowledge and capabilities required to leverage the full potential of iPSCs can limit its application.
For more than a decade, Ncardia has been pioneering innovations in iPSCs to transform therapeutic development in human healthcare. The combined iPSC expertise and in-house technology enables Ncardia offering unique integrated solutions for cell manufacturing and screening.
Starting with experimental scale, the manufacturing procedures are designed to scale up to state-of-the-art stirred-tank bioreactors in the shortest possible time frame, mitigating risks and with minimal batch-to-batch variability.
Join this presentation and gain insights about how Ncardia partners with biotech and pharma companies and constantly develops new manufacturing procedures for complex iPSC-derived cells which are characterized with identity and functional assays.